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The primary objective of this study was to define the pH conditions under which 
supplemental pancreatic enzyme preparations must function in the upper gastrointestinal 
tract. The hypothesis was that normal or greater gastric acid output in patients with cystic 
fibrosis (CF), combined with low pancreatic bicarbonate output, results in an acidic 
duodenal pH, compromising both dosage-form performance and enzyme activity. Gas- 
trointestinal pH profiles were obtained in 10 CF and 10 healthy volunteers under fasting 
and postprandial conditions. A radiotelemetric monitoring method, the Heidelberg 
capsule, was used to continuously monitor pH. Postprandial duodenal pH was lower in 
CF than in healthy subjects, especially in the first postprandial hour (mean time greater 
than pH 6 was 5 min in CF, 11 min in healthy subjects, P < 0.05). Based on the dissolution 
pH profiles of current enteric-coated pancreati c enzyme products, the duodenal 
postprandial pH in CF subjects may be too acidic to permit rapid dissolution of current 
enteric-coated dosage forms. However, the pH was above 4 more than 90% of the time on 
the average, suggesting that irreversible lipase inactivation in the duodenum is not likely 
to be a significant limitation to enzyme efficacy. Overall results suggest that slow 
dissolution of pH-sensitive coatings, rather than enzyme inactivation, may contribute to 
the failure of enteric-coated enzyme supplements to normalize fat absorption. 
KEY WORDS: cystic fibrosis; gastrointestinal pH; pancreatic therapy enzyme. 
In 80-85% of patients with cystic fibrosis (CF), 
there is sufficient loss of pancreatic exocrine func- 
tion to produce clinically evident malabsorption (1). 
It has been suggested that the degree of pancreatic 
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insufficiency may be important to the overall prog- 
nosis in CF patients (2). For example, patients with 
uncorrected malabsorption have altered serum lipid 
profiles (3, 4). Moreover, normal fat absorption 
appears to be correlated with better pulmonary 
function (5). Some authors have suggested that the 
development of pancreatic insufficiency is the basic 
defect in CF, with other manifestations of CF 
resulting from secondary malnutrition (6). Success- 
ful correction of malabsorption in CF patients may 
therefore be an important therapeutic goal. 
Enzyme supplements constitute the primary ap- 
proach to treating pancreatic insufficiency. Al- 
though these supplements substantially reduce fat 
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excretion, they usually fail to bring stool fat levels 
within the normal range (7-19). Inactivation by 
gastric acid is a major limitation to enzyme efficacy 
(20, 21) unless the dosage form is enteric-coated. 
The limited data available (19, 22, 23) suggest that 
the duodenum is more acidic in CF than healthy 
subjects. At least two aspects of enzyme replace- 
ment therapy could be detrimentally affected by low 
duodenal pH. First, enzyme release may be pre- 
vented by failure of the enteric coating to dissolve. 
Polymers used to enteric-coat dosage forms have 
dissolution times which are highly pH-sensitive. 
Time to dissolve varies from virtually infinity at low 
pH (1-'2) to just  a few minutes at neutral pH. The 
exact crossover pH from slow to fast dissolution 
depends on the pKa of the polymer used. If the 
duodenal/jejunal pH is lower than the crossover 
pH, the coating may take a long time to dissolve, 
preventing enzyme release during a major portion 
of the small intestinal transit. The second potential 
problem resides with changes in enzyme activity as 
a function of pH. 
The present study was undertaken to compare 
the gastrointestinal pH profiles of CF and healthy 
subjects. Our aim was to determine the extent to 
which low duodenal pH in CF subjects may limit 
the efficacy of currently available enzyme supple- 
ments,  by comparing postprandial duodenal pH 
with (1) the pH profile for enteric coating dissolu- 
tion and (2) the pH dependency of enzyme activity. 
MATERIALS AND METHODS 
Subject Selection. The study was carried out in the 
Clinical Research Center of The University of Michigan 
Hospitals on an outpatient basis, with approval of the 
Human Subject Review Committee. All participants gave 
written informed consent (parental consent in the case of 
minors). 
Ten subjects (five female, five male) with documented 
cystic fibrosis were selected from the population attend- 
ing the University of Michigan Cystic Fibrosis Clinic. 
Age ranged from 10.5 to 20 years with a mean of 13.2 
years. All participants were prescribed pancreatic en- 
zymes at the time of the study. The study was restricted 
to patients with Shwachman scores of over 40. Patients 
with Clinical or laboratory evidence of cardiac disorders, 
diabetes mellitus, and hepatobiliary, renal, or other gas- 
trointestinal disease were excluded. Pulmonary functio n 
was stable wlth varying severity among the selected 
participants. None were taking antacids or H2-receptor 
antagonists or receiving oxygen therapy. Other medica- 
tions were recorded for each participant. A summary of 
CF subject data is given in Table 1. Ten healthy volun- 
teers (five female, five male adults), mean age 24 years 
(range 21-29 years) were selected to serve as controls. 
None of the healthy participants had historic, clinical, or 
laboratory evidence of gastrointestinal disease, nor were 
any on chronic medication. Smoking, alcohol, and caf- 
feine were disallowed three days prior to and throughout 
the study. A 500-mg dose of bentiromide (N-berizolyl-L- 
tyrosyl para-aminobenzoic acid) was administered to 
each subject to assess pancreatic function (24-27). All 
healthy subjects excreted at least 50% PABA, indicating 
pancreatic sufficiency with respect to chymotrypsin. The 
10 CF subjects had less than 50% PABA excretion, 
indicating pancreatic insufficiency. 
pH Measurement. Continuous determination of pH 
with time was accomplished using a radiotelemetric de- 
vice, the Heidelberg capsule (28-33). The device consists 
of a battery-powered high-frequency radio transmitter 
and a pH electrode housed in a nondigestible acrylic 
capsule 7 mm in diameter and 20 mm in length. The 
frequency of transmission changes with the pH of the 
capsule's environment and can be calibrated using stan- 
dard buffer solutions. The subject wears an antenna 
TABLE 1. CYSTIC FIBROSIS SUBJECT DATA 
Enzyme therapy 
Age Weight Height Shwachman and capsules Chymex | (% 
Subject (years) percentile percentile score per meal* excretion) 
Females 
K.Y. 14 <3 7 60 C/6 14 
S.M. 11 25 34 73 P/3 20 
Rh.G. 12 20 25 66 C/3 17 
Ro.G. 10.5 10 3 70 C/5 29 
S.W. 15 15 7 64 C/4 35 
Males 
J.W. 20 86 25 71 C/2 47 
J.D. 16 <3 8 65 P/4-5 18 
B.B. 16 44 30 72 P/3 46 
R.V. 13 <3 3 48 P/4 38 
D.T. 15 <3 <3 57 C/6-8 37 
*C = Cotazym-S; P = Pancrease. 
.*Used normal weight percentiles for 18 years olds. 
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strapped around the midriff to receive the radio signal, 
which is converted back to pH and recorded as a function 
of time. 
A modified calibration procedure was used to ensure 
the desired accuracy of _+0.5 pH units throughout the 
study period. Capsules were activated the evening prior 
to the study and calibrated just before being administered 
to the subject. In vitro studies were conducted at 37 ~ C to 
confirm that this calibration procedure resulted in -+0.5 
pH unit accuracy over an 8-hr study period. Readings in 
pH 1 and 7 buffer solutions maintained at 37~ were 
taken at 2-hr intervals for 8 hr, and recorded pH was 
compared with actual buffer pH to confirm that the 
capsule maintained the desired accuracy. At the end of 
each tethered capsule study, the capsule was recovered 
and its response to pH 1 and 7 buffers checked against the 
prestudy values. 
Study Design. The participants fasted for at least 12 hr 
before swallowing a tethered Heidelberg capsule. Gastric 
pH was monitored until the capsule emptied into the 
small intestine, an event marked by a mpi& unreversed 
elevation in pH. After the capsule emptied from the 
stomach, it was allowed to travel approximately 10 cm 
further (ie, to the mid to distal portion of the duodenum), 
then the position was fixed by taping the tether thread 
(Braunamid surgical thread) to the subject's cheek. This 
procedure resulted in a tether length of 60-70 cm from the 
teeth in the younger CF subjects and 70--80 cm in adult 
CF and healthy subjects. In a separate study, the corre- 
spondence of this tethering procedure to a mid/distal 
duodenal location was verified by fluoroscopy. Fasting 
pH in the duodenum was recorded for 30 min, then a 
standard meal consisting of 6 oz of hamburger, 2 slices of 
bread, 2 oz Of hash brown potatos, 1 tablespoon ketchup, 
1 oz each of tomato and lettuce, 1 tablespoon of mayon- 
naise, and 8 oz of milk (for a total of 1000 calories) was 
given. CF subjects were permitted to take their usual 
enzlyme supplements with the meal. POstprandial pH in 
the duodenum was monitored for 4 hr. 
' ~ Further experiments were conducted in the same sub- 
jects to determine pH over the entire length of the small 
intestine. Subjects fasted for at least 12 hr, then swal- 
lowed an untethered, calibrated Heidelberg capsule, pH 
was continuously monitored for at least 7 hr as the 
capsule passed through the gastrointestinal tract under 
the auspices of natural motility. 
Dosage-Form EvaLuation. United States Pharmacopeia 
(USP) (34) disintegration apparatus was used to test two 
enteric-coated multiparticulate enzyme preparations, 
Cotazym-S and Pancrease. The USP test consists of 
visually following the disintegration (break-up into fine 
particles) of the dosage form on wire screens attached to 
the bottom of Plexiglas columns. Six dosage forms are 
tested per experiment, each dosage form in a separate 
column. The columns are mechanically moved up and 
down 30 times per minute in a fluid medium. This process 
is quite vigorous, so the times observed using the USP 
apparatus probably represent minimum times required for 
disintegration. The endpoint is taken as the time required 
for all the dosage form material to pass through the 
Screen. Note that for an enteric-coated dosage form, the 
disintegration requires two steps. First, the coating must 
dissolve, then the spherule must break up into a fine 
powder. Citrate/phosphate buffers were used to adjust the 
disintegration medium to the desired pH. Disintegration 
testing was carried out at 37 ~ C at pH 5.2 through pH 7.0. 
We were thus able to determine the minimum pH re- 
quired for rapid coating dissolution, disintegration of the 
spherules, and subsequent enzyme release for both 
Cotazym-S and Pancrease. 
Data Analysis. The pH and time values were sampled 
directly from the gastrointestinal pH profiles, and data 
analyzed using CLINFO (35) software. Descriptive sta- 
tistics are reported as mean values ___ SEM. Student's t 
tests (two sample and paired) were used to investigate 
differences in gastric emptying times and fasting gastro- 
intestinal pH values between the healthy and CF groups. 
The postprandial data is reported as the percentage of 
time in each postprandial hour spent above pH 4, 5, 5.5, 
and 6. Time above the pH of interest was measured for 
each hour, divided by 60 min (total time), and multiplied 
by 100 to calculate percent time. Statistical postprandial 
differences between the CF and healthy groups were 
determined using a nonpaired Wilcoxon rank sum test. 
RESULTS 
Twenty-two of the 23 capsules used remained 
within calibration when recovered  at the end of  the 
tethered capsule study. Mean readings were 1.0 -+ 
0.05 and 6.9 -- 0.05 in the pH i and 7 buffers, 
respectively. The pH profile from the study day on 
which the capsule failed to maintain accuracy was 
excluded from data analysis. 
In the tethered capsule study, fasting gastric pH 
ranged between 1 and 5 for all subjects. For  18 of  
the 20 subjects,  the pH was predominantly between 
pH 1 and 2. In some subjects the pH became more 
variable close to gastric emptying of  the capsule. 
Representat ive gastroduodenal  pH profiles are 
shown in Figure 1. Typical  gastric pH and gastric 
emptying times (time between swallowing the 
Heidelberg capsule and its passage into the duode- 
num) are given in Table 2. No significant differences 
were seen between CF and healthy subjects in 
either gastric pH or gastric emptying time of the 
capsule. 
Results for postprandial duodenal pH are summa- 
rized for all subjects in Figure 2. Examinat ion of  
fasting duodenal profiles (first half hour  after the 
capsule emptied from the stomach) indicated that 
there was wider fluctuation o f p H  in CF subjects (an 
average of  3.1 units between minimum and maxi- 
mum value observed in the 30-rain period) than in 
healthy subjects (average of  1.8 units minimum to 
maximum). Nine of  10 CF subjects exper ienced a 
variation of greater than 2 units compared  to three 
of 10 healthy subjects (P < 0.01). 
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Fig 1. Typical pH profiles recorded in the study. GET corresponds to gastric emptying of the capsule. Thirty minutes elapsed between 
tethering the Heidelberg capsule in the duodenum and giving a standard meal (indicated by arrow). 
In eight of 10 healthy subjects there was a rise of 
0.5 to 1 pH unit in the duodenum as the subject 
started to eat. In one of the remaining two subjects, 
the pH was already greater than 7. It is postulated 
that the initial rise corresponds to the cephalic phase 
of pancreatic secretion, including bicarbonate. After 
this brief phase (5-10 min), acid deflections began to 
occur, continuing throughout the postprandial period. 
These occurred at a frequency of one every minute or 
so, although the rate was highly variable. The de- 
crease in pH during the deflection often exceeded 1 
pH unit, corresponding to a 10-fold or higher increase 
in hydrogen ion concentration, but quickly reverted to 
the predeflection level. Over the 4-hr postprandial 
period, there was an overall trend for the duodenal pH 
to decrease. 
Postprandial pH in duodena of CF subjects fol- 
lowed a qualitatively similar pattern to that of 
healthy subjects, in that the pH fluctuated repeat- 
edly after eating and that there was a tendency for 
pH to decrease with time. However,  two key de- 
partures were noted. First, in CF subjects the initial 
rise in duodenal pH in response to meal intake was 
absent in all but one pH profile. Second, post- 
prandial pH tended to be lower in CF than healthy 
subjects in all 4 hr, with the difference significant in 
the first hour at a 95% confidence level (mean time 
greater than pH 6 was 5 min in CF, 11 min in 
healthy subjects) (see Table 4 below). The trend 
toward more acidic pH with time was seen in CF as 
well as healthy subjects. For example, an average 
of 21% of the time was spent above pH 5.5 in the 
first hour in CF subjects; by the fourth hour only 9% 
of the time was spent at pH above 5.5. 
TABLE 2. GASTRIC PH AND EMPTYING TIME OF HEIDELBERG CAPSULE IN CF 
AND HEALTHY SUBJECTS 
CF Healthy 
Mean minimum gastric pH 0.9* 1.3 
Mean maximum gastric pH 1.8 2.1 
Range of gastric pH < 1-4.7 < 1-3.2 
Gastric emptying time of Heidelberg capsule 116 -+ 25 77 +- 19 min 
*This value must be regarded as approximate since the lower limit of calibration 
of the Heidelberg capsule is pH 1. 
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Fig 2. Percentage of time spent above pH 6.0 and pH 5.5 in each postprandial hour in the 
duodenum. Solid bars represent data from healthy volunteers, open bars represent data 
from CF subjects. 
In the untethered capsule study, fasted pH in the 
small intestine of CF subjects (Figure 3) was signif- 
icantly lower just after gastric emptying (upper 
small intestine) and again at 3 hr postemptying, than 
in healthy subjects. Moreover, the mean pH in CF 
subjects was always pH 6.0 or below, whereas in 
healthy subjects, mean intestinal pH climbed to pH 
6.4 within 2.5 hr after the capsule was emptied from 
the stomach. 
In Vitro Studies. Disintegration times as a func- 
tion of buffer pH for Cotazym-S and Pancrease are 
listed in Table 3. The enteric coating of Cotazym-S 
only dissolves rapidly, ie, within 15 min of expo- 
sure, at pH of 6.2 or higher, whereas rapid dissolu- 
tion of the Pancrease coating occurs at pH 5.6 and 
above. 
DISCUSSION 
Conventional dosage forms of pancreatin consist 
of enzyme powder, either packed in capsules or 
loose, and enzyme tablets. Although they reduce fat 
excretion, these preparations do not fully normalize 
fat absorption (7-19). The chief limitation to their 
efficiency is thought to be inactivation of enzymes 
by gastric acid. Secretion of gastric acid in response 
to meals has been studied in both healthy and CF 
subjects. In healthy subjects, the meal initially 
buffers and dilutes the gastric contents to a pH of 5 
or so (36, 37). Postprandial gastric acid secretion 
quickly results in a lowering of the pH--below 3 
within 60 min and returning to a baseline value of 2 
or lower by the end of the second hour. Cameron et 
al (38) observed postprandial gastric pH profiles in 
CF subjects that were similar to those in healthy 
volunteers. Other groups (10, 39, 40) have also 
observed normal or higher acid output in CF sub- 
jects. Although we did not measure stimulated 
gastric acid response, our results for fasting gastric 
pH were similar in CF and healthy subjects and are 
therefore consistent with normal gastric acid func- 
tion in CF subjects. 
In the fasting state, with the capsule tethered in 
the duodenum, the pH was observed to fluctuate 
over a wider range (P < 0.02) in CF than healthy 
subjects, indicating poorer ability to regulate pH in 
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Fig 3. S u m m a r y  of  fasting small-intestinal pH data over  a 3-hr period of intestinal  transit .  
Squares  represent  mean  pH  - SEM in the heal thy subjects .  Circles represent  mean  pH  - SEM 
in the  C F  subjects .  *Statistical difference in pH be tween  the heal thy and CF subjects  (P < 
0.05). 
CF. Fluctuations in duodenal pH in patients with 
pancreatic dysfunction have also been observed by 
Dutta et al (41) and Benn and Cooke (42). The mean 
and range of fasting duodenal pH in CF subjects 
(X= 5.1, range 3.3-6.4 after 30 min in the duode- 
num) was in good agreement with data of Abrams et 
al (22) (X = 5.0, range 3-6.7) and Knauff and Adams 
(43) X" = 4.8, range 2-6.9). Likewise, the fasting 
duodenal pH in healthy subjects (X = 5.7, range 
TABLE 3. DISINTEGRATION TIME AS A FUNCTION OF PH FOR 
COTAZYME-S. AND PANCREASE (AVERAGE OF Six 
EXPERIMENTS) 
Time to Disintegrate (min) 
pH Cotazym-S Pancrease 
5.2 >120 >120 
5.4 >120 33 - 5 
5.5 * 40 - 4 
5.6 96 -+ 30 10 -+ 0.5 
6.0 31 -+ 23 10 +-- 1 
6.1 33 -+ 26 * 
6.2 12 -+ 1 * 
7.0 13 --- 1 * 
*Not  tes ted at g iven pH.  
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5.0-6.9 after 30 min in the duodenum) was similar to 
previously reported results (37, 44, 45). 
At the start of the meal, we observed a transient 
rise in duodenal pH in most healthy subjects but 
only in one CF subject. These observations would 
be consistent with a failure in CF subjects to secrete 
bicarbonate ion as part of the cephalic response to 
meal intake. 
We observed consistently lower postprandial 
duodenal pH in CF compared with healthy subjects, 
in concurrence with three studies reported in the 
literature. Weber and Roy (19) observed post- 
prandial pH lower than 4 in two CF subjects. 
Isenberg and Powell (23) observed pH of less than 
5.1 in almost half the meal fractions aspirated from 
three CF subjects with steatorrhea. Abrams et al 
(22) found that the average basal duodenal pH in 
five adult male CF subjects was pH 5, with the pH 
dropping to 4.4 by the second postprandial hour. 
We also observed a trend for the pH to decrease 
with time during the postprandial period. This trend 
was observed for the healthy subjects as well, 
consistent with data reported by other groups (36, 
42, 49, 50). However,  the time spent above pH 5.5 
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as well as the overall pH was always lower in CF 
subjects in any given hour. 
Three ways in which an acidic postprandial duo- 
denal pH could compromise enzyme performance 
are (1) to reduce lipase activity and, at sufficiently 
low pH, to irreversibly inactivate lipase, (2) to 
cause bile acid precipitation, and (3) to prevent 
dissolution of the coating on enteric-coated formu- 
lations. 
Apparent lipase activity is quite pH-dependent. 
Go et al (46) found a 10-fold decrease in activity 
between pH 6 and 3. Similarly, Dressman et al (47) 
reported a three- to fourfold decrease in lipase 
activity of commercial preparations when lipolysis 
was compared at pH 5 with pH 8, the optimal pH 
for the enzyme. Below pH 5, the efficiency of 
lipolysis is additionally compromised by bile acid 
precipitation (46, 48). At very acidic pHs (below 4), 
lipase is irreversibly inactivated (20, 21, 47). Com- 
paring our pH data with these findings suggests that 
lipolysis would be somewhat less efficient in CF 
subjects. 
From the mean data (Table 4), it appears that 
only a very short time was spent below pH 4 in 
either group of subjects. Appraisal of the data on an 
individual basis is somewhat more revealing. Three 
CF subjects had duodenal pH below 4 for substan- 
tial periods. Abrams et al (22) reported a similar 
incidence (two of five subjects). Overall, however, 
it appears, that irreversible lipase inactivation as a 
result of low duodenal pH is not a major limitation 
to enzyme activity--in most subjects the pH is not 
remarkably lower than in healthy subjects, and 
those that did exhibit low pH (S.W., J.W., B.B.) are 
not the most malnourished. A further point to note 
is that time below pH 5 was very similar for the two 
subject groups. This suggests that precipitation of 
bile acids occurs to about the same extent in CF and 
healthy subjects and is therefore probably not the 
limiting factor to lipolysis. 
In both subject groups, the duodenal pH is below 
the pH for optimal lipase activity. This apparently 
does not present a problem in healthy subjects who 
secrete excess quantities of lipase in response to a 
meal. In CF subjects, however, the dose of en- 
zymes administered may be insufficient or substan- 
tial degradation may occur in the stomach (eg, with 
conventional dosage forms). In such cases the low 
amount of lipase reaching the duodenum combined 
with suboptimal conditions for activity could result 
in incomplete fat digestion. 
The third consideration is the ability of enteric- 
coated products to release their contents in the 
small intestine. Enteric coating is a favored ap- 
proach to circumventing gastric inactivation of en- 
zyme products. In this case a coating which is 
impervious to acid but dissolves at a more neutral 
pH is used to protect the enzymes against the high 
acid concentration in the stomach. In vitro tests 
have shown that uncoated preparations quickly lose 
activity at gastric pH, whereas enteric-coated prod- 
ucts retain a high percentage of activity (51). 
Comparing postprandial duodenal pH data with 
pH dependency of disintegration times enabled us 
to assess the importance of pH limitations to 
enteric-coated dosage form performance. For in- 
stance, at pH 6.0, Cotazym-S takes 31 - 23 min to 
disintegrate, yet during the first postprandial hour 
the duodenal pH in CF subjects is above 6 for an 
average of only 5 min. It should be noted that 
disintegration of the dosage form is just the first step 
in enzyme release; the enzymes must subsequently 
dissolve before becoming fully active. It is therefore 
unlikely that efficient release of enzymes from this 
dosage form would occur in the postprandial CF 
duodenum. Pancrease spherules disintegrate within 
10 min at pH of 5.6 or higher. Since about 12 min/hr 
TABLE 4. TIME SPENT IN VARIOUS PH RANGES IN HEALTHY (H) AND CF 
POSTPRANDIAL DUODENUM (MIN/HR • SEM) 
Hour  
p H  range 
>4.0 >5.0 >5.5 >6.0 
CF 58.9 + 0.5 41.6 --- 3.7 12.6 - 2.9 4.9 • 2.2 
H 59.8 • 0.2 45.0 _-2 4.3 20.3 + 3.2 10.7 • 2.2 
CF 56.7 • 1.5 36.7 -+ 4.4 10.2 • 3.2 4.4 - 2.7 
H 56.2 --- 2.0 31.8 • 5.2 14.1 --- 4.4 4.0 -+ 2.0 
CF 52.3 • 3.9 25.6 --- 5.7 8.5 --- 3.4 3.0 • 1.7 
H 57.7 --- 0.9 33.6 --- 4.3 11.0 • 3.5 3.1 +-- 2.0 
CF 52.2 • 2.5 25.3 --- 5.3 5.4 • 2.1 1.1 • 0.5 
H 55.3 - 1.6 28.8 -+ 3.9 10.0 -+ 3.0 1.7 • 1.1 
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of the first two postprandial hours are spent at pH 
5.5 or higher, spherules emptying during this period 
would take almost an hour to release their enzyme 
content. By the fourth postprandial hour, pH is 
above 5.5 for less than 10 min/hr, indicating that the 
coating may take longer than an hour to dissolve 
and release the enzymes. While the Pancrease 
disintegration/pH profile is more favorable than the 
Cotazym-S profile, it still may not provide for 
efficient digestion as there would be a lag time on 
the order of an hour between emptying of spherules 
from the stomach and onset of digestive action. 
Presumably both preparations would eventually re- 
lease their enzyme content at more distal, higher- 
pH locations. Cameron et al (38), found that the 
mean proximal jejunal pH in four CF subjects 
ranged from pH 5.7 to 6.5 in a 90-min postprandial 
observation period. 
In the second part of our study in CF subjects, 
fasting gastrointestinal pH was observed as a func- 
tion of time following administration of an 
untethered Heidelberg capsule. It was found that 
the pH reached 6 at an average of 90 min after the 
capsule passed from the stomach into the small 
intestine. At pH 6, coating dissolution requires 
about 10-15 min, so the total time elapsed prior to 
enzyme release would be approximately 100 min. 
Comparing this release time to the usual small- 
intestine transit time of just under 200 min for an 
inert object of similar dimensions to the Heidelberg 
capsule (53), it appears that as much as half the 
available contact time between chyme and enzymes 
could be lost because of the high pH required to 
dissolve the coating. The reduced contact time 
might be insufficient for digestion to be completed 
prior to entry of the chyme into the colon. Recently 
published data for jejunal pH in pancreatic insuffi- 
cient adults and healthy volunteers indicates that 
jejunal pH is the same or lower in the postprandial 
than the fasted state (Ovesen et al, Gastroenterol- 
ogy 90:958, 1986). Our estimates for contact time of 
enzymes with chyme after administration of 
enteric-coated dosage fo rms  are based on fasted 
intestinal pH data and may therefore tend to over- 
estimate available contact time in the fed state. 
From the results presented here, it appears that 
prolonged coating dissolution time, possibly exac- 
erbated by a suboptimal lipase activity-dose com- 
bination, provides a reasonable explanation for the 
inability of Cotazym-S and Pancrease to fully nor- 
malize absorption. A comparison of stool fat after 
direct perfusion of enzymes into the duodenum 
versus administering a comparable dose orally 
would be required to determine the extent of for- 
mulation limitations to enzyme performance. 
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